New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
10:56 EDTNRF, NKTR, PQ, DBD, HMSYHigh option volume stocks: HMSY PQ NRF DBD NKTR
News For HMSY;PQ;NRF;DBD;NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
07:05 EDTDBDDiebold backs FY15 non-GAAP EPS $1.70-$1.90, consensus $1.80
Backs FY15 revenue to decline 5%-6%, consensus $2.91B.
07:04 EDTDBDDiebold expects to place more emphasis on mix of revenue
CEO Andy Mattes commented, “We're encouraged with the progress we've made since we introduced our Diebold 2.0 transformation in 2013, with a strong emphasis on reducing our cost structure, improving our cash flow, building talent and making the investments necessary to grow the company. These pillars will remain important during the next phase of our transformation. Looking forward, we will place more emphasis on improving our mix of revenue to include a higher ratio of recurring services and software, which typically improves visibility and value. We remain encouraged with our opportunities and are confident in our ability to position Diebold for long-term success.”
07:04 EDTDBDDiebold reports Q2 non-GAAP EPS 44c, consensus 39c
Subscribe for More Information
July 21, 2015
10:01 EDTHMSYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:07 EDTHMSYHMS Holdings price target lowered to $18 from $27 at Baird
Subscribe for More Information
06:57 EDTHMSYHMS Holdings downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
July 20, 2015
16:22 EDTHMSYOn The Fly: Top stock stories for Monday
Subscribe for More Information
08:34 EDTHMSYHMS Holdings to protest NJ Medicaid third party liability contract award
After the markets closed on Friday, July 17, HMS Holdings Corp. received notification from the State of New Jersey Division of Purchase and Property, Procurement Bureau of its intent to make a contract award for Third Party Liability Services to a competitor, pursuant to the State's RFP 15-x-23249. HMS intends to protest the proposed award to Public Consulting Group, consistent with the Division’s administrative regulations, and will also consider any and all legal remedies as appropriate. "We are committed to the third-party liability business we perform for state customers throughout the nation. We have served the State of New Jersey for nearly 30 years and recovered hundreds of millions of dollars for the State Treasury. We believe our experience and qualifications as a third-party liability vendor for state Medicaid programs are unmatched in the industry and that does not appear to be reflected in the scoring of our RFP response," said Bill Lucia, Chairman and CEO.
July 16, 2015
15:42 EDTNKTRNektar partner Baxalta releases complete data from Phase II/III BAX 855 study
Nektar Therapeutics (NKTR) reported that partner Baxalta announced the publication of the complete data from the Phase II/III pivotal study and Phase I trial of BAX 855 in Blood, the journal of the American Society of Hematology. BAX 855 is Baxalta's investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE, a leading treatment for hemophilia A with more than 11 years of real-world patient experience. Through a collaboration with Nektar, BAX 855 leverages proprietary pegylation technology designed to prolong the amount of factor VIII available for use in the body. As previously disclosed, BAX 855 met the study's primary endpoint for the prevention of bleeding episodes and the treatment with prophylaxis compared to on-demand treatment. Patients in the twice-weekly prophylaxis arm of the trial experienced a 95% reduction in median annualized bleed rate as compared with those in the on-demand arm. BAX 855 was also effective in treating all bleeding episodes, 95.9% of which were controlled with one or two infusions at a median dose of 29.0 IU/kg per infusion.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use